|1.||Diamandis, Eleftherios P: 125 articles (07/2015 - 01/2002)|
|2.||Scorilas, Andreas: 59 articles (07/2015 - 05/2002)|
|3.||Yousef, George M: 42 articles (07/2015 - 05/2002)|
|4.||Diamandis, E P: 34 articles (09/2013 - 03/2000)|
|5.||Chao, Julie: 29 articles (05/2013 - 03/2002)|
|6.||Soosaipillai, Antoninus: 26 articles (09/2014 - 01/2002)|
|7.||Clements, Judith A: 26 articles (09/2014 - 05/2003)|
|8.||Chao, Lee: 26 articles (05/2013 - 03/2002)|
|9.||Lilja, Hans: 25 articles (08/2015 - 02/2007)|
|10.||Yousef, G M: 20 articles (09/2013 - 03/2000)|
08/01/2015 - "We confirmed that human urinary kallidinogenase improved stroke outcome in patients. "
08/01/2015 - "To investigate whether human urinary kallidinogenase's efficacy in treating stroke patients has relationship with improving cerebral perfusion and possible mechanism. "
09/01/1999 - "This is the first study to demonstrate the protective effect of kallikrein gene delivery in reducing salt-induced stroke mortality and vascular dysfunction."
08/01/2015 - "Human urinary kallidinogenase has been shown promising in treating stroke patients. "
08/01/2015 - "Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging."
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "Of these, approaches to measure distinct molecular forms of PSA (free, intact, complexed PSA, and pro-PSA) combined with kallikrein-related peptidase 2 (KLK2), also known as hK2, have been considered holding particular promise in enhancing the diagnosis of prostate cancer. "
06/01/2006 - "Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network."
01/01/2012 - "The Kallikrein-related peptidase, KLK4, has been shown to be significantly overexpressed in prostate tumours in numerous studies and is suggested to be a potential biomarker for prostate cancer. "
08/24/2010 - "A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands."
06/15/2010 - "A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam."
04/15/2012 - "Results showed that human urinary kallidinogenase improved symptoms of neurological deficiency by enhancing remodeling of long-term cortical motor function in patients with acute cerebral infarction. "
01/01/2015 - "Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction."
07/01/2015 - "In accordance with randomized controlled trial, 110 patients with acute cerebral infarction were randomly assigned to kallikrein treatment group (55 cases) and control group (55 cases). "
04/15/2012 - "A total of 29 patients were treated within 48 hours after acute subcortical cerebral infarction with Xuesaitong or Xuesaitong plus human urinary kallidinogenase for 14 days. "
04/15/2012 - "Remodeling of motor cortex function in acute cerebral infarction patients following human urinary kallidinogenase: A functional magnetic resonance imaging evaluation after 6 months."
04/01/2014 - "Within the Ser-protease group, the kallikrein-related peptidase (KLK) family, which encompasses a subgroup of 15 members, holds particular promise, with some acting via a tumor-promoting mechanism and others behaving as protective factors. "
07/01/2015 - "A panel of four kallikrein immunoassays has been reported to improve the prediction of prostate biopsy outcome (cancer vs benign) in men with elevated PSA in the circulation. "
12/01/2015 - "Re: Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study."
07/01/2015 - "Free, intact and total PSA, and kallikrein-related peptidase 2 were measured in cryopreserved blood from 6129 men with elevated PSA (≥3.0ng/mL) participating in the prospective, randomized trial Prostate Testing for Cancer and Treatment. "
07/01/2015 - "Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study."
01/01/1985 - "Infertile men with sperm count below 20 X 10(6)/ml had greater improvement in sperm count than men with sperm count over 20 X 10(6)/ml. This study emphasizes that kallikrein is a relatively good drug for restoring sperm motility in idiopathic oligoasthenozoospermia and asthenozoospermia."
01/01/1985 - "A randomised group of 75 men with idiopathic oligoasthenozoospermia and asthenozoospermia were subjected to control study with kallikrein. "
01/01/1992 - "An application of Kallikrein in the swim-up preparation resulted in a higher motility in patients with asthenozoospermia, whereas the patients belonging to the group of oligoasthenozoospermia showed a lower progressive motility compared to the control. "
01/01/1991 - "While the groups normo-, oligo-, and asthenozoospermia reached a higher fertilizing capacity under Kallikrein-treatment (probability of error 2.5%), a Kallikrein application in case of oligo-asthenozoospermia had no significant influence on fertilizing capacity. "
10/13/1989 - "147 patients with isolated asthenozoospermia treated by means of 600 IU kallikrein daily showed a resultant significant elevation (p less than 0.002) in sperm motility only. "
|1.||Tissue Kallikreins (Tissue Kallikrein)
|5.||Serine Proteases (Serine Protease)
|6.||Prostate-Specific Antigen (Semenogelase)
|7.||Messenger RNA (mRNA)
|8.||Protein Isoforms (Isoforms)
|9.||Complementary DNA (cDNA)
|1.||Blood Transfusion (Blood Transfusions)
|2.||Drug Therapy (Chemotherapy)
|3.||Prostatectomy (Retropubic Prostatectomy)
|4.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|5.||Estrogen Replacement Therapy